Trial Profile
A Randomized, Double Blind, Comparative, Phase II/III Study to Evaluate the Immunogenicity and Safety of Three Formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcgg (adjuvanted)] of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 6 - 35 Months of Age.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors Panacea Biotec
- 30 Dec 2010 New trial record